Authors’ response to ‘Comment on ‘Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial’’

We thank Quispe Calla and colleagues for their insightful comments on our article. We agree that basic science evidence showing that various progestogens increase HIV susceptibility is compelling. We also agree that randomised clinical trials (RCTs) are informative regarding the relative risks of HIV between contraceptive alternatives, but not the absolute risks compared with no contraception. However, it is likely that all non-barrier contraceptives increase absolute HIV risk because women wishing to avoid pregnancy are more likely to engage in unprotected sexual intercourse when the fear of pregnancy is reduced. Therefore, for women who desire contraception, it is the relative risk between the available options that is important. As Calla and colleagues point out, the relative effect of other non-barrier contraceptives including levonorgestrel-releasing intrauterine systems on susceptibility to HIV is unexplored.

The reason that clinical trials are needed to complement the basic science data is that human HIV risk is a composite of biological, physiological and behavioural effects. While the data presented by Calla and colleagues suggest that progestogen contraception increases biological risk, we have previously suggested that physiological and behavioural effects may reduce risk. These include reduced risk of viral exposure during menstruation (unpublished data from our study showed that 75% of women experienced amenorrhoea with injectable progestogens) and reduced unprotected sexual exposure due to reduced libido. Therefore we maintain that relative net biological, physiological and behavioural effects between contraceptive alternatives can only be determined by RCTs.

G Justus Hofmeyr
Effective Care Research Unit, Eastern Cape, Department of Health, Universities of the Witwatersrand, Walter Sisulu and Fort Hare, East London, South Africa; justhof@gmail.com

Theresa Anne Lawrie
Effective Care Research Unit, Eastern Cape, Department of Health, Universities of the Witwatersrand, Walter Sisulu and Fort Hare, East London, South Africa
Royal United Hospital, Bath, UK; tess@lawrie.com

Corresponding author

Contributors GJH wrote this letter on behalf of all the study authors.

Competing interests None declared.

Provenance and peer review Commissioned; internally peer reviewed.

© Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Published Online First 23 August 2017

REFERENCES